DM-CHOC-PEN

Drug Profile

DM-CHOC-PEN

Alternative Names: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine; Penclomidine derivative

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator Dekk-Tec
  • Class Antineoplastics; Carbonates; Picolines
  • Mechanism of Action Alkylating agents; Cell cycle modulators; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Brain cancer; Brain metastases
  • Phase I Cancer; Solid tumours

Most Recent Events

  • 31 Aug 2016 Dekk-Tec plans a phase II trial for Cancer (Late-stage disease, Second-line therapy or greater, In infants, In children, In adolescents) in USA (IV) (NCT02889445)
  • 01 Jun 2016 Dekk-Tec completes a phase II trial in Brain metastases and Brain cancer in USA (NCT02038218)
  • 16 Apr 2016 Pharmacokinetics, efficacy and safety data from phase I and phase II trials in Solid tumours (including brain cancer/metastases) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top